Last updated: 2026-09-16 14:41:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Scilex Holding Company (SCLX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $5.13, with a market capitalisation of $35.88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.20 to $34.27. This page covers its latest market performance, valuation, price trends and company information.
$35.88M | |
$4.97 | |
$591.50 | |
$3.60 | |
$4.93 | |
656.00 | |
105.74K | |
-- | |
$34.27 | |
$4.20 | |
-- | |
-- |
Scilex Holding Company (SCLX) is currently trading at $5.13 as of 2026-09-16 14:38:00, up 3.96% ($0.20) from the previous close of $4.93
During today's regular trading session, SCLX has traded between $3.60 and $591.50, with a trading volume of 656.00 shares. The current price is near the lower end of today's range.
Over the past seven days, Scilex Holding Company (SCLX) moved from $5.42 to $5.13, representing a decline of 5.36% ($0.29).
The stock traded between $4.85 and $5.72 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 30.68 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.1%
SCLX is currently trading at $5.13, placing it 3.1% of the way from its 52-week low of $4.20 to its 52-week high of $34.27. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 34 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Scilex Holding Company (SCLX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.